"instanceType","description","rationale","name","label","id","uuid:ID"
"StudyDesign","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1","","StudyDesign_1","ff7b3ee2-18da-47dd-9174-7dad8d4a89ce"
